CDC.govRare diseaseSwiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3Swiss clinical-stage biotech Vaderis Therapeutics has raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing, backed … more ➔
Mimetas BVOrganoids and Lab-on-chipBruker Takes Majority Stake in dutch MIMETAS as Organoid Technologies Move Into the MainstreamThe U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology … more ➔
Knowbio with Sweden.seCancerSwedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3Swedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. … more ➔
licensingActimed retrieves ALS drug after Faraday collapseUK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, … more ➔
fundraisingMironid lands $46M Series B to take kidney drug into clinicScottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through … more ➔
clinical trialEvexta pairs ex-Merck drug with Roche’s giredestrantFrench biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer. more ➔
licensingAstraZeneca taps Pathos for breast cancer degraderAstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agree … more ➔
oncologyIpsen quietly returns cancer drug IPN01194 to AGV DiscoveryIpsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery. more ➔
rare diseasesSobi’s dealmaker CEO exits for BioNTechGuido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue … more ➔
M&AAstraZeneca explores $400B combination with BMSAstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported. more ➔
CDC.gov
Mimetas BV
Knowbio with Sweden.se
